Amy S. Clark, MD, MSCE

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-154
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-662-7096
Fax: 215-615-3349
Education:
BS (Biology)
Haverford College, 1999.
MD (Medicine)
Milton S. Hershey Penn State College of Medicine, 2006.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2012.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

I am a medical oncologist who specializes in breast cancer. I only see breast cancer patients in the outpatient setting, but treat patients will all cancers when working in the hospital.

Description of Research Expertise

My research focuses on clinical trials and drug development for those with early stage and metastatic breast cancer. I also seek to develop novel predictive biomarkers specifically using molecular imaging as companions to early phase trials.

Selected Publications

Miller KD, Zhao F, Clark AS, Wilkinson G, Heineman T, Wolff A: BRACELET-1 (PrE0113): A Study To Assess Overall Response Rate By Inducing An Inflammatory Phenotype In Metastatic Breast Tumors With The Oncolytic Reovirus Pelareorep In Combination With Anti-PD-L1 Avelumab And Paclitaxel. ASCO Annual Meeting 2021 June 2021 Notes: submitted for ASCO Annual Meeting 2021.

Chein AJ, Soliman H, Ewing C, Boughey JC, Campbell MJ, Rugo HS, Schwab R, Maure M, Wong J, Wallace A, Hieken TJ, Degnim AC, Albanien KS, Goodellas C, Stringer-Reasor E, Church A, Kalinsky K, Elias A, Mitri Z, Clark AS, Nanda R, Thomas A, Han H, Isaacs C, Lang JE, Yau C, Yee D, DeMichele AM, Perlmutter J, Hilton NM, Symmans WF, Melisko ME, van't Veer LJ, I-SPY 2 Consortium, Wilson A, Lu R, Asare SM, Sanil A, Berry DA, Esserman LJ: Evaluation of Intra-tumoral (IT) SD-101 and Pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 TRIAL. ASCO Annual Meeting 2021 June 2021 Notes: Submitted to ASCO Annual Meeting 2021.

Chien AJ, Soliman H, Ewing C, Boughey JC, Campbell MJ, Rugo HS, Schwab R, Majure M, Wong J, Wallace A, Hinken TJ, Degnim AC, Albanien KS, Godellas C, Stringer-Reasor E, Church A, Kaminski K, Elias A, Mitri Z, Clark AS, Nanda R, Thomas A, Han H, Isaacs C, Lang JE, Yau C, Yee D, DeMichele AM, Perlmutter J, Hilton NM, Symmans WF, Melisko ME, van't Veer LJ, I-SPY 2 Consortium, Wilson A, Lu R, Asare SM, Sanil A, Berry DA, Essermen LJ: Evaluation of Intra-tumoral (IT) SD-101 and Pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 TRIAL. ASCO Annual Meeting 2021 June 2021 Notes: submitted to ASCO Annual Meeting 2021.

Takvorian SU, Parikh RB, Vader D, Wileyto EP, Clark AS, Lee DJ, Goyal G, Rocque GB, Dotan E, Geynisman DM, Full P, Spiess PE, Kim RY, Davidoff AJ, Gross CP, Miksad RA, Clip GS, Shulman LN, Mamtani E, Hubbard RA: Impact of COVID-19 pandemic on time to treatment initiation for patients with advanced cancer. ASCO Annual Meeting 2021 June 2021 Notes: Submitted to ASCO Annual Meeting 2021.

Chein AJ, Soliman H, Ewing C, Boughey JC, Campbell MJ, Rugo HS, Schwab R, Maure M, Wong J, Wallace A, Hieken TJ, Degnim AC, Albanien KS, Goodellas C, Stringer-Reasor E, Church A, Kalinsky K, Elias A, Mitri Z, Clark AS, Nanda R, Thomas A, Han H, Isaacs C, Lang JE, Yau C, Yee D, DeMichele AM, Perlmutter J, Hilton NM, Symmans WF, Melisko ME, van't Veer LJ, I-SPY 2 Consortium, Wilson A, Lu R, Asare SM, Sanil A, Berry DA, Esserman LJ: Evaluation of Intra-tumoral (IT) SD-101 and Pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 TRIAL. ASCO Annual Meeting 2021 June 2021 Notes: Submitted to ASCO Annual Meeting 2021.

Clark AS, Elmi A, McAndrew N, Wileyto EP, Shih N, Feldman M, Rosen M, Savage J, Holmes R, DiNubile N, Berger TE, Schubert E, Matthai A, Volpe M, Shah PD, Matro J, Domchek S, Mankoff D, DeMichele A: Cell cycle synchronization: Biomarker analysis in a phase I trial of alternating ribociclib and paclitaxel in advanced breast cancer AACR Annual Meeting 2021 April 2021 Notes: Accepted for ePoster Presentation AACR Annual Meeting 2021.

Clark AS, Yau C, Wolf DM, Petricoin EF, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Albain KS, Tripathy D, Ellis ED, Forero-Torres A, Yung R, Han HS, Lang JE, Viscusi RK, Haley BB, Kemmer K, Elias AD, Nanda R, Boughey JC, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA,Alvarado M, Crane EP, Robinson P, Buxton M, Clennell JL, Paolini M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare AL, Matthews J, Berry S, Snail A, Melissa M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hilton NM, Yee D, Van 't Veer LJ, Berry DA, Esserman LJ, DeMichele AM: Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2- positive breast cancer in the adaptively randomized I-SPY2 trial. Cancer Cell 2021 Notes: manuscript under review

Clark AS: Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1). AACR 2021.

Okines A, Paplomata E, Wahl T, Wright G, Sutherland S, Jakosen E, Valdes-Albini F, Chan A, Clark AS, Conlin A, Lustberg M, Specht J, Pluard T, Zhu X, Krop I, Gelmon K, Slamon D, Ramos J, An G, Hamilton E: Management of Adverse Events in Patients with HER2+ Metastatic Breast Cancer Treated with Tucatinib, Trastuzumab, and Capecitabine (HER2CLIMB) Journal of Clinical Oncology, American Society of Clinical Oncology Annual Meeting, Chicago, IL. Jun 2020 Notes: "Poster Presentation"

Haddad T, D'Assoro A, Suman V, Carter J, McMenomy B, Mayer E, Karuturi M, Morikawa A, Marcom P, Isaacs C, Young Oh S, Clark A, Mayer I, Keyomarsi K, Leon-Ferre R, Giridhar K, O'Sullivan C, Peethambaram P, Hobday T, Liu M, Ingle J, Goetz M: Randomized phaseII trial to evaluate alisertib alone or combined with fulvestrant for advanced, endocrine-resistant breast cancer (TBCRC 041). San Antonino Breast Cancer Symposium, Virtual Dec 2020 Notes: Poster.

back to top
Last updated: 04/15/2021
The Trustees of the University of Pennsylvania